BC 007

A ssDNA aptamer.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

Supporting references

Contradictory references

AI-suggested references

Clinical trials

BC 007 is an ssDNA aptamer clinically tested for its ability to eliminate autoantibodies against the beta1 adrenergic receptor (NCT04192214).

Link	Tested on	Impact factor	Notes	Publication date
Aptamer BC 007 - Efficient binder of spreading-crucial SARS-CoV-2 proteins DNA Biophysical assay In vitro	in vitro biophysical assay		Observed to bind peptide sequences of SARS-CoV-2 RNA-dependent RNA polymerase and spike protein in vitro.	Oct/31/2020

Link	Publication date
Aptamer BC 007's Affinity to Specific and Less-Specific Anti-SARS-CoV-2 Neutralizing Antibodies.	May/18/2021
Case Report: Neutralization of Autoantibodies Targeting G-Protein-Coupled Receptors Improves Capillary Impairment and Fatigue Symptoms After COVID-19 Infection	Feb/19/2021